Shortly after the World Health Organization (WHO) announced that Covaxin had been added to its Emergency Use Listing, the US Centers for Disease Control and Prevention revealed that the vaccine would be recognized for travel to the US.
Accordingly, this means that starting from November 8, when the US will open its borders for travel from Schengen Area countries, the UK, Ireland, South Africa, Brazil, India, and China, all persons who have been vaccinated against the COVID-19 disease with Coaxin will be permitted entry into the country for non-essential purposes, after over a year and a half of not having been able to do so.
“The Technical Advisory Group, convened by WHO and made up of regulatory experts from around the world, has determined that the Covaxin vaccine meets WHO standards for protection against COVID19, that the benefit of the vaccine far outweighs risks & the vaccine can be used,” WHO wrote on its official Twitter account, commenting on the vaccine’s approval.
Except for the newly recognized vaccine, based on the current entry rules that the US has, travelers who hold a vaccination certificate indicating full immunization with one of the other recognized vaccines – Moderna, Pfizer/BioNTech, Johnson & Johnson, AstraZeneca, Covishield, Sinopharm, Sinovac – are also permitted to enter the country.
According to a press release that has been issued by WHO on November 3, Covaxin was assessed under WHO procedure based on the review of data on safety, quality, efficacy, a risk management plan, and programmatic suitability.
Therefore, the Technical Advisory Group, made up of regulatory experts from around the world and convened by WHO, has determined that Covaxin, which was developed by Bharat Biotech, meets WHO standards for protection against the COVID-19 and far outweighs the risks, VisaGuide.World reports.
“This emergency use listing expands the availability of vaccines, the most effective medical tools we have to end the pandemic. But we must keep up the pressure to meet the needs of all populations, giving priority to the at-risk groups who are still waiting for their first dose, before we can start declaring victory,” WHO Assistant-Director General for Access to Medicines and Health Products, Dr. Mariângela Simão said.
The vaccine is formulated from an inactivated Coronavirus antigen and is presented in single-dose vials and multidose vials of five, ten, and 20 doses.
The Strategic Advisory Group of Experts on Immunization has recommended that the vaccine be administered in two doses in all age groups 18 and above. Regarding pregnant women, it has been highlighted that there isn’t any available data yet; however, initial trials have been reassuring.
Covaxin has proven to have an efficacy of 78 percent against COVID-19 of any severity and is exceptionally suitable to countries with low and middle incomes due to its easy storage requirements.
It is highly suggested that everyone who plans on traveling amid the COVID-19 pandemic checks the validity of their vaccine by using a vaccine-checker tool developed by VisaGuide.World, which enables travelers worldwide to verify if the vaccine they have been immunized with is accepted by their destination country.